Immunotherapy
FDA Approves Pembrolizumab and Durvalumab for Endometrial Cancer Treatment
FDA, Pembrolizumab, Durvalumab, Endometrial Cancer, Immunotherapy, Chemotherapy
ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment
ASCO 2024, Opdivo-Yervoy, Bristol Myers Squibb, Liver Cancer, First-Line Treatment, Roche, AstraZeneca, Immunotherapy, CheckMate-9DW
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Lung Cancer Trial, but Shows Promise in Subgroup Analysis ###
Gilead Sciences, Trodelvy, Lung Cancer, ASCO, FDA, Clinical Trials, Oncology, Immunotherapy, Trop-2 Directed Antibody-Drug Conjugate
AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody
AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer
FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.
Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma
Bristol Myers, Breyanzi, CAR-T therapy, follicular lymphoma, FDA approval, cancer treatment, immunotherapy.
Bristol Myers’ Breyanzi Approved by FDA for Follicular Lymphoma, Joining Gilead and Novartis in CAR-T Treatment
Bristol Myers, Breyanzi, FDA, follicular lymphoma, CAR-T, Gilead, Novartis, cancer treatment, immunotherapy
Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership
Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Keytruda Fails to Show Significant Benefit in Newly Diagnosed Endometrial Cancer Patients
Keytruda, endometrial cancer, clinical trial, newly diagnosed, immunotherapy, treatment, cancer therapy, clinical outcomes.
CG Oncology’s Immunotherapy Shows Promising Complete Response Rate in Bladder Cancer Patients
CG Oncology, immunotherapy, bladder cancer, complete response rate, clinical trials, cancer treatment.